cannabidiol and Weight-Gain

Topics: Animals; Cannabidiol; Cannabis; Dronabinol; Endocannabinoids; Glucose; Mice; Mice, Inbred C57BL; Obesity; Weight Gain

Use of medical cannabis for improving symptoms of inflammatory bowel disease is increasing. However, reports on long-term outcomes are lacking. This prospective, observational study assessed the effects of licensed cannabis use among patients with inflammatory bowel disease.. Dose and mode of consumption, adverse events, use of other medications, and long-term effects were evaluated among 127 patients with inflammatory bowel disease using legalized medical cannabis. Blood count, albumin, and C-reactive protein were assessed before, 1 month, and at least 1 year after medical cannabis therapy was initiated. Questionnaires on disease activity, patient function, and signs of addiction were completed by patients and by a significant family member to assess its effects.. The average dose used was 31 ± 15 g/month. The average Harvey-Bradshaw index improved from 14 ± 6.7 to 7 ± 4.7 (P < 0.001) during a median follow-up of 44 months (interquartile range, 24-56 months). There was a slight, but statistically significant, average weight gain of 2 kg within 1 year of cannabis use. The need for other medications was significantly reduced. Employment among patients increased from 65 to 74% (P < 0.05). We conclude that the majority of inflammatory bowel disease patients using cannabis are satisfied with a dose of 30 g/month. We did not observe negative effects of cannabis use on the patients' social or occupational status.. Cannabis use by inflammatory bowel disease patients can induce clinical improvement and is associated with reduced use of medication and slight weight gain. Most patients respond well to a dose of 30 g/month, or 21 mg Δ9-tetra- hydrocannabinol (THC) and 170 mg Cannabidiol (CBD) per day.

Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; C-Reactive Protein; Cannabidiol; Dronabinol; Drug Administration Routes; Employment; Female; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Israel; Male; Medical Marijuana; Mesalamine; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Serum Albumin; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Weight Gain; Young Adult

Topics: Adipogenesis; Adiposity; Animals; Biomarkers; Body Composition; Cannabidiol; Cell Differentiation; Diet, High-Fat; Feeding Behavior; Fibroblast Growth Factors; HEK293 Cells; Hormones; Humans; Insulin Resistance; Male; Mice, Inbred C57BL; Obesity; Osteoblasts; PPAR gamma; Weight Gain

The biological activities of cannabidiol (CBD), a major non-psychotropic constituent of the fiber-type cannabis plant, have been examined in detail (e.g., CBD modulation of body weight in mice and rats). However, few studies have investigated the biological activities of cannabidiol-2',6'-dimethyl ether (CBDD), a dimethyl ether derivative of the parent CBD. We herein focused on the effects of CBDD on body weight changes in mice, and demonstrated that it stimulated body weight gain in apolipoprotein E (ApoE)-deficient BALB/c. KOR/Stm Slc-Apoe(shl) mice, especially between 10 and 20 weeks of age.

Topics: Age Factors; Animals; Apolipoproteins E; Cannabidiol; Male; Mice, Inbred BALB C; Mice, Transgenic; Stimulation, Chemical; Weight Gain

Individuals with wasting syndrome lose muscle or lean body mass rather than body fat. Several possible alternatives to the approved drugs for AIDS-related wasting are discussed. Ketotifen, an antihistamine approved in Europe, is a TNF inhibitor. Anabolic steroids are testosterone derivatives designed to increase strength and muscle. Although there are anecdotal reports of success with these steroids, their long-term safety and efficacy have yet to be established in placebo-controlled studies. An ongoing study at Mt. Sinai shows a statistically significant effect on lean body mass in the first twelve men to complete the study. Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal gland. Although its role in the body is poorly understood; it may have immunologic effects, and appears to influence metabolism. There have been no studies of DHEA's effect on weight or body composition in people with AIDS-related wasting. A study combining ketotifen and oxymetholone, the oral anabolic steroid, was presented at the Ninth International AIDS Conference. Preliminary data from a study combining ketotifen and oxymetholone showed that 18 out of 22 patients gained an average of 11.4 pounds after treatment of an average of 3.9 weeks. Finally, a trial of smoked marijuana versus the oral drug marinol for AIDS-related wasting syndrome may be canceled. The Drug Enforcement Administration (DEA) and the National Institute of Drug Abuse (NIDA) rejected the Community Consortium of San Francisco's proposal to obtain officially sanctioned cannabis.

Topics: Acquired Immunodeficiency Syndrome; Anabolic Agents; Cannabidiol; Dronabinol; Female; Humans; Ketotifen; Male; Marijuana Smoking; National Institutes of Health (U.S.); Quality of Life; Tumor Necrosis Factor-alpha; Weight Gain